Alison M. Schram, MD, spoke about key findings from the phase 2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive advanced solid tumors.
Alison Schram, MD
Advertisement
Articles by Alison Schram, MD
CancerNetwork® sat down with Alison Schram, MD, to discuss her thoughts on research with the greatest potential to positively influence patient care being presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
